Stryker recently secured FDA clearance for its OptaBlate BVN system, aiming to enhance its portfolio in advanced pain therapy solutions. The company's share price rose 14% over the past month.

Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic * vertebrogenic low back pain. "We often see patients with chronic low back pain ...

Stryker said Monday that its OptaBlate basivertebral nerve ablation system received 510(k) clearance from the Food and Drug Administration. The medical technology company said its OptaBlate BVNA ...

Ronda E Stryker, Director at Stryker SYK, executed a substantial insider sell on May 8, according to an SEC filing. Stryker designs, manufactures, and markets an array of medical equipment ...

Welcome to the First Quarter 2025 Stryker Earnings Call. My name is Luke and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Following the ...

EL PASO, TEXAS - Key leaders from 2nd Stryker Brigade Combat Team, 4th Infantry Division, Joint Task Force-Southern Border (JTF-SB) convened in El Paso, Texas, May 7, 2025 to synergize efforts ...

Joseph M. Terranova of Virtus Investment Partners names Stryker. Brian Belski picks Rockwell Automation as his final trade. Memorial Day Special: Access your full investing command center with ...

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements ...

Stryker Corporation, a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $143 billion, reported strong earnings for Q1 2025, surpassing analysts ...

Some of the resources sent to southern Arizona include the 2nd Stryker Brigade Combat Team from Colorado. They have soldiers on Fort Huachuca and spread throughout Arizona, New Mexico, and Texas.

“It is an extreme honor to be awarded the Randjelović/Stryker Residency and commission in this moment when arts funding is disintegrating and health care and the cost of living in New York City ...

“Our 2024 momentum continued into the first quarter as we delivered double-digit organic sales growth and continued to expand adjusted operating margins,” said Kevin A. Lobo, Chair and CEO.